CAMBRIDGE, Mass. — Vyome Holdings, Inc. announced results from an independent U.S. market assessment and valuation analysis indicating that its lead clinical candidate, VT-1953, could be valued at nearly $1 billion following the successful completion of a Phase 3 clinical study.
The analysis, commissioned by Vyome and conducted by life sciences advisory firm Destum Partners, evaluated the commercial potential of VT-1953, which is being developed for the treatment of symptoms associated with malignant fungating wounds, a rare and severe complication of advanced solid tumors characterized by malodor, pain, and significant psychosocial distress.
According to the assessment, the total addressable pharmacologic market in the United States for malignant fungating wounds is estimated at approximately $2.2 billion. Based on a bottom-up commercial forecast, modeled peak annual U.S. net sales for VT-1953 are projected to approach $600 million. Using a risk-adjusted net present value methodology, the analysis estimates the current U.S. asset value of VT-1953 at approximately $455 million following positive Phase 2 data, rising to nearly $1 billion upon successful completion of a Phase 3 study.
“Malignant fungating wounds represent one of the most severe and underserved conditions in oncology supportive care,” said Tom Filipczak, Managing Director and Partner at Destum Partners. “Our team conducted rigorous primary and secondary research, including clinician interviews, epidemiology modeling, pricing benchmarking, and valuation analyses. Based on the absence of approved therapies and the high unmet need, we believe this indication represents a compelling clinical and commercial opportunity.”
Vyome said the independent analysis supports its view of the clinical and commercial potential of VT-1953, particularly in an area where no FDA-approved pharmacologic treatments are currently available.
“This independent analysis reinforces our conviction in the potential of VT-1953,” said Venkat Nelabhotla, Chief Executive Officer of Vyome. “We engaged a highly experienced third-party consulting firm to conduct a rigorous and unbiased assessment of the commercial opportunity for this program, where there are currently no FDA-approved drugs. Destum Partners’ conclusion around the total addressable market in the U.S., together with the modeled potential peak sales and significant post-Phase 3 potential valuation, provides important external validation as we seek to advance VT-1953 toward pivotal development.”
Destum Partners’ analysis incorporated extensive secondary research, epidemiology modeling, evaluation of the competitive landscape, pricing benchmarks, and interviews with key opinion leaders across oncology, palliative care, wound care, and hospice settings.
